Immunitybio logo

Immunitybio Stock

StockStock
ISIN: US45256X1037
Ticker: IBRX
US45256X1037
IBRX

Price

Frequently asked questions

What is Immunitybio's market capitalization?

The market capitalization of Immunitybio is $3.37B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Immunitybio?

Immunitybio's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.867. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Immunitybio's stock?

Currently, 2 analysts cover Immunitybio's stock, with a consensus target price of $7.50. Analyst ratings provide insights into the stock's expected performance.

What is Immunitybio's revenue over the trailing twelve months?

Over the trailing twelve months, Immunitybio reported a revenue of $7.33M.

What is the EBITDA for Immunitybio?

Immunitybio's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$340.77M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Immunitybio?

Immunitybio has a free cash flow of -$434.10M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Immunitybio's stock?

The 5-year beta for Immunitybio is 0.74. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Immunitybio have, and what sector and industry does it belong to?

Immunitybio employs approximately 672 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Immunitybio's shares?

The free float of Immunitybio is 159.61M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$3.37B

5Y beta

 
0.74

EPS (TTM)

 
-$0.867

Free Float

 
159.61M

Revenue (TTM)

 
$7.33M

EBITDA (TTM)

 
-$340.77M

Free Cashflow (TTM)

 
-$434.10M

Pricing

1D span
$4.648$5.092
52W span
$3.10$10.53

Analyst Ratings

The price target is $7.50 and the stock is covered by 2 analysts.

Buy

1

Hold

1

Sell

0

Information

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

672

Biotechnology & Drugs

Health Care

Identifier

ISIN

US45256X1037

Primary Ticker

IBRX

Knockouts

Join the conversation